[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369438-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369438-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","characterization-of-the-neoantigen-profile-in-a-tumor-mutation-burden-high-melanoma-patient-with-multiple-metastases-abstract-and-methods-results","Characterization of the Neoantigen Profile in a Tumor Mutation Burden-high Melanoma Patient With Multiple Metastases - Abstract and Methods - Results","","Neoantigen (NA) profiling is used to support development of novel immunotherapies, and prior work showed a melanoma case with high tumor mutation burden achieving complete remission after anti-programmed death-1 therapy. The study reexamines the same patient, characterizing NA profiles of additional metastatic lesions using in silico HLA-binding predictions and in vitro CTL assays. It analyzes immunological status in metastatic sites through gene expression, immunohistochemistry, and tumor-infiltrating lymphocytes with TCR repertoire profiling. Genomic and functional analyses identify shared and site-specific driver mutations and variable immune responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characterization-of-the-neoantigen-profile-in-a-tumor-mutation-burden-high-melanoma-patient-with-multiple-metastases-abstract-and-methods-results/369438/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characterization-of-the-neoantigen-profile-in-a-tumor-mutation-burden-high-melanoma-patient-with-multiple-metastases-abstract-and-methods-results/369438.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of characterizing the neoantigen profile in this melanoma case?","Question",{"text":63,"@type":64},"To profile neoantigens and investigate the immunological status across multiple metastatic sites, including tumor-infiltrating lymphocytes and the TCR repertoire during progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were neoantigen candidates selected for evaluation?",{"text":68,"@type":64},"Candidates from whole-exome sequencing were filtered using HLA-binding predictions (NetMHCpan 4.1), selecting HLA-A*2402-restricted sequences with strong predicted binding, followed by assessment of synthetic peptide candidates.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the genomic analysis show across metastatic sites?",{"text":72,"@type":64},"All metastatic sites contained more than 1,500 SNVs and shared 12 driver mutations. Additional site-specific driver mutations were identified in intra-muscular and brain metastases, including a JAK1 mutation linked to increased invasion activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369438,1790443257,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","doi: 10.21873/cgp.20517  \nCharacterization of the Neoantigen Profile in a Tumor Mutation Burden‐high Melanoma Patient With Multiple Metastases  \nSHUSUKE YOSHIKAWA1*, CHIE MAEDA2*, AKIRA IIZUKA2, TOMOATSU IKEYA2, KAZUE YAMASHITA2, TADASHI ASHIZAWA2, AKARI KANEMATSU2, HARUO MIYATA2, YASUFUMI KIKUCHI2, KENICHI URAKAMI3, KEIICHI OHSHIMA4, TAKESHI NAGASHIMA3,5, KEN YAMAGUCHI6, YOSHIO KIYOHARA1 andYASUTOAKIYAMA2  \n1 Division of Dermatology, Shizuoka Cancer Center Hospital, Shizuoka, Japan;  \n2 Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan;  \n3Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan;  \n4 Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan;  \n5SRL Inc., Tokyo, Japan;  \n6Office of the President Emeritus, Shizuoka Cancer Center, Shizuoka, Japan  \nAbstract  \nBackground/Aim: Recently, neoantigen (NA) profiling has been intensively performed for the development of novel immunotherapy. We previously reported a melanoma case with a high tumor mutation burden that achieved complete remission after anti‑programmed death‑1 therapy. We herein revisited the same case, characterized the NA profiles of other metastatic lesions using in silico algorithms and in vitro CTL assays, and investigated the immunological status, including tumor‑infiltrating lymphocytes and the T cell receptor (TCR) repertoire profile, in metastatic sites. Materials and Methods: NA candidates obtained from whole‑exome sequencing were applied totheHLA‑binding prediction algorithm, NetMHCpan4.1. HLA‑A*2402‑restricted sequence candidates with a strong binding capacity (\u003C50 nM) andelution affinity (\u003C1%) were selected and evaluated for synthetic peptide candidates. The immunological status in metastatic sites was characterized using gene expression profiling, immunohistochemistry, and a TCR repertoire analysis.  \nResults: The genomic analysis revealed that all metastatic sites, such as costal, intra‑muscular, and brain lesions, had >1,500 SNVs, and 12 driver mutations were common to all sites. New driver mutations were identified in intra‑ muscular (KMT2C: p.P3292S) and brain (JAK1: p.S404P) metastases and a functional analysis of these mutations revealed that JAK1 mutation exhibited a promoting effect on invasion activity. CTL assays using synthetic NA peptides identified more NA epitopes in brain metastasis.  \ncontinued  \n*These Authors contributed equally to this work.  \n✉Yasuto Akiyama, Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi‑  \ncho, Sunto‑gun, Shizuoka 411‑8777, Japan. Tel: +81 559895222 (Ext. 5330), Fax: +81 559896085, e‑[mail: y.akiyama@scchr.jp](mail: y.akiyama@scchr.jp)  \nReceived December 23, 2024 | Revised January 16, 2025 | Accepted January 31, 2025  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2025 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nConclusion: These results might suggest that the heterogeneity of driver gene mutations is unremarkable, while immunological response is variable in metastatic sites. As a result, the genomic and immunological investigation has provided a very valuable and informative suggestion regarding better cancer therapy decisions.  \nKeywords: High TMB melanoma, multiple metastases, neoantigens, driver gene mutations, immunological status.  \nIntroduction  \nWith advances in next‑generation sequencing (NGS) technology and RNA sequencing, the identification of novel neoantigens (NA) mainly derived from passenger mutations has been successful in many clinical trials on immune checkpoint blockade therapy (1‑3) . Specific complex NA‑based peptide or mRNA vaccines comprising multiple NA‑derived mutant sequences have been developed in early‑phase cl","cbCaiu261Z2Mj0Ol","https://ap.wps.com/l/cbCaiu261Z2Mj0Ol","pdf",2610819,14,"English","# Abstract\n## Background/Aim\n## Materials and Methods\n## Results\n# Introduction\n# Materials and Methods","[{\"question\":\"What is the main goal of characterizing the neoantigen profile in this melanoma case?\",\"answer\":\"To profile neoantigens and investigate the immunological status across multiple metastatic sites, including tumor-infiltrating lymphocytes and the TCR repertoire during progression.\"},{\"question\":\"How were neoantigen candidates selected for evaluation?\",\"answer\":\"Candidates from whole-exome sequencing were filtered using HLA-binding predictions (NetMHCpan 4.1), selecting HLA-A*2402-restricted sequences with strong predicted binding, followed by assessment of synthetic peptide candidates.\"},{\"question\":\"What did the genomic analysis show across metastatic sites?\",\"answer\":\"All metastatic sites contained more than 1,500 SNVs and shared 12 driver mutations. Additional site-specific driver mutations were identified in intra-muscular and brain metastases, including a JAK1 mutation linked to increased invasion activity.\"}]","Characterization of the Neoantigen Profile in a Tumor Mutation Burden-high Melanoma Patient With Multiple Metastases - Abstract and Methods - Results | PDF",1790182666,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/350e919ef20b82481d619b3ec79723ae.webp",983,1301,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fca3c84dce63010d19786b765182a9bf.webp",982,1299,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03384518f313691d85c973c4b013d2d2.webp",981,1298,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af5e8ebc3f288ee181283084271a31d3.webp",980,1297]